| |
NewswireTODAY - /newswire/ -
Winston-Salem, NC, United States, 2012/07/11 - Small Caps in the news for Wednesday, Get Real USA, Inc. (Pinksheets: GTRL) $0.018, Orexigen Therapeutics (Nasdaq: OREX) $5.98 and Capstone Turbine Corporation (Nasdaq: CPST) $1.04.
|
| |
Get Real USA, Inc. (Pinksheets: GTRL) $0.018. Announced Tuesday after market close that Mr. Gregory Walker is joining Get Real USA, Inc. as an entertainment finance and production advisor.
"We believe the addition of Mr. Walker will bring unparalleled enthusiasm, leadership skills and in depth knowledge of movie production and movie finance to Get Real USA," said Aaron Johnson, Chairman of the Company. "His insights and advice could be the catalyst to propel Get Real USA into a major player in the production of high quality independent films."
Mr. Walker manages a film tax credit fund that has produced, executive produced and provided tax credit finance solutions for over 55 movies. He is also owner and operator of Louisiana Media Productions (LAMP), located in Baton Rouge, Louisiana. LAMP's sister company, Post Matters, is a 22,000 sq. feet full scale premiere post production facility that will now be available to Get Real USA.
Some of Mr. Walker's extensive movie credits include: Universal Soldier: Day of Reckoning starring Jean-Claude Van Damme, Flypaper starring Patrick Dempsey and Ashley Judd, El Gringo starring Christian Slater, and Arena starring Samuel L. Jackson.
"Get Real USA clearly believes in aiming high with our corporate goals. And we also recognize one of the keys to achieving these goals is our very talented team of management and advisors. Greg Walker promises to become an invaluable to asset to Get Real USA future success and we're thrilled to have him on board," added Mr. Johnson.
What They Do: Get Real USA, Inc. is comprised of top-notch industry professionals with years of experience and success in the film industry.
Orexigen Therapeutics (Nasdaq: OREX) $5.98. Today announced an update to the projected timeframe for completion of enrollment of the Light Study, the Contrave® cardiovascular outcomes clinical trial. Orexigen now expects to complete enrollment of patients required for the interim analysis of the Light Study in the first quarter of 2013, potentially reducing by half the original projections.
"2012 has been a year of focused execution at Orexigen in order to conduct the Light Study as quickly as possible," said Michael Narachi, CEO of Orexigen. "The outstanding efforts of our team and our partners have resulted in enrollment rates of the targeted population that are much faster than originally expected."
What They Do:Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity.
Capstone Turbine Corporation (Nasdaq: CPST) $1.04. Today announced it recently received multiple orders from two natural gas service companies in Colombia that total two megawatts of prime power generation.
The first of the two new orders secured by Capstone Distributor Supernova Energy Services was for the purchase of two Capstone Microturbines --a C1000 and C200--which will be used in a combined heat and power (CHP) application for a large gas treatment plant near Yopal, Colombia. The energy generated will provide 100 percent of the power for the facility, and the heat will be utilized in the gas treatment process. The Capstone microturbine will enable the facility to increase the volume of gas treated while generating reliable power.
What They Do: Capstone Turbine Corporation is the world's leading producer of low-emission microturbine systems, and was the first to market commercially viable microturbine energy products.
About SmallCapReview
SmallCapReview.com has been a leading site for information on Small Cap Stocks, Penny Stocks and Microcaps since 1999. SmallCapReview has been compensated three thousand five hundred dollars by a third party APS for its efforts with regards to Get Real USA.
|
editor[.]smallcapreview.com 
